checkAd

     145  0 Kommentare Y-mAbs Announces U.S. FDA Acceptance of Biologics License Application for Danyelza (naxitamab) for the Treatment of Neuroblastoma for Priority Review - Seite 2

    Contact:

    Lesen Sie auch

    Y-mAbs Therapeutics, Inc.
    230 Park Avenue, Suite 3350
    New York, NY 10169
    USA 
    +1 646 885 8505 
    E-mail: info@ymabs.com



    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 2 von 2

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Y-mAbs Announces U.S. FDA Acceptance of Biologics License Application for Danyelza (naxitamab) for the Treatment of Neuroblastoma for Priority Review - Seite 2 NEW YORK, June 02, 2020 (GLOBE NEWSWIRE) - Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic …